163 related articles for article (PubMed ID: 32537694)
21. Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment.
Finch AP; Gamper E; Norman R; Viney R; Holzner B; King M; Kemmler G;
Pharmacoeconomics; 2021 Sep; 39(9):1085-1098. PubMed ID: 34216380
[TBL] [Abstract][Full Text] [Related]
22. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
[TBL] [Abstract][Full Text] [Related]
23. Order of Presentation of Dimensions Does Not Systematically Bias Utility Weights from a Discrete Choice Experiment.
Norman R; Kemmler G; Viney R; Pickard AS; Gamper E; Holzner B; Nerich V; King M
Value Health; 2016 Dec; 19(8):1033-1038. PubMed ID: 27987630
[TBL] [Abstract][Full Text] [Related]
24. Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format.
Norman R; Viney R; Aaronson NK; Brazier JE; Cella D; Costa DS; Fayers PM; Kemmler G; Peacock S; Pickard AS; Rowen D; Street DJ; Velikova G; Young TA; King MT
Qual Life Res; 2016 Mar; 25(3):637-49. PubMed ID: 26342928
[TBL] [Abstract][Full Text] [Related]
25. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.
Pilz MJ; Seyringer S; Hallsson LR; Bottomley A; Jansen F; King MT; Norman R; Rutten MJ; Leeuw IMV; Siersema PD; Gamper EM
Eur J Health Econ; 2024 Mar; ():. PubMed ID: 38483665
[TBL] [Abstract][Full Text] [Related]
26. The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.
Gamper EM; Cottone F; Sommer K; Norman R; King M; Breccia M; Caocci G; Patriarca A; Palumbo GA; Stauder R; Niscola P; Platzbecker U; Caers J; Vignetti M; Efficace F
J Clin Epidemiol; 2021 Sep; 137():31-44. PubMed ID: 33753228
[TBL] [Abstract][Full Text] [Related]
27. Health state utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS Preference Score.
Klapproth CP; Fischer F; Rose M; Karsten MM
J Clin Epidemiol; 2022 Dec; 152():101-109. PubMed ID: 36162712
[TBL] [Abstract][Full Text] [Related]
28. Health utility assessments in individuals undergoing diagnostic and surveillance colonoscopy: improved discrimination with a cancer-specific scale.
Bulamu NB; Chen G; McGrane E; Cock C; Young GP; Symonds EL
Cancer Causes Control; 2024 Feb; 35(2):347-357. PubMed ID: 37747615
[TBL] [Abstract][Full Text] [Related]
29. The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation study.
McTaggart-Cowan H; King MT; Norman R; Costa DSJ; Pickard AS; Viney R; Peacock SJ;
Health Qual Life Outcomes; 2022 Jun; 20(1):97. PubMed ID: 35710417
[TBL] [Abstract][Full Text] [Related]
30. Health-Related Quality of Life Associated with Barrett's Esophagus and Cancer.
Bulamu NB; Chen G; Ratcliffe J; Schloite A; Bright T; Watson DI
World J Surg; 2019 Jun; 43(6):1554-1562. PubMed ID: 30719557
[TBL] [Abstract][Full Text] [Related]
31. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
[TBL] [Abstract][Full Text] [Related]
32. Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping.
Yang M; Vioix H; Hook ES; Hatswell AJ; Batteson RL; Gaumond BR; O'Brate A; Popat S; Paik PK
Value Health; 2023 Aug; 26(8):1155-1163. PubMed ID: 36805576
[TBL] [Abstract][Full Text] [Related]
33. The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set.
King MT; Norman R; Mercieca-Bebber R; Costa DSJ; McTaggart-Cowan H; Peacock S; Janda M; Müller F; Viney R; Pickard AS; Cella D;
Value Health; 2021 Jun; 24(6):862-873. PubMed ID: 34119085
[TBL] [Abstract][Full Text] [Related]
34. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.
Kim SH; Jo MW; Kim HJ; Ahn JH
Health Qual Life Outcomes; 2012 Dec; 10():151. PubMed ID: 23244763
[TBL] [Abstract][Full Text] [Related]
35. Erratum to: QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30.
King MT; Costa DSJ; Aaronson NK; Brazier JE; Cella DF; Fayers PM; Grimison P; Janda M; Kemmler G; Norman R; Pickard AS; Rowen D; Velikova G; Young TA; Viney R
Qual Life Res; 2016 Oct; 25(10):2683. PubMed ID: 27060088
[No Abstract] [Full Text] [Related]
36. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
[TBL] [Abstract][Full Text] [Related]
37. Second Version of the Short Form 6-Dimension Value Set Elicited From Patients With Breast and Colorectal Cancer: A Hybrid Approach.
Touré M; Pavic M; Poder TG
Med Care; 2023 Aug; 61(8):536-545. PubMed ID: 37308990
[TBL] [Abstract][Full Text] [Related]
38. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
39. Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
Beck ACC; Kieffer JM; Retèl VP; van Overveld LFJ; Takes RP; van den Brekel MWM; van Harten WH; Stuiver MM
PLoS One; 2019; 14(12):e0226077. PubMed ID: 31834892
[TBL] [Abstract][Full Text] [Related]
40. United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument.
King MT; Revicki DA; Norman R; Müller F; Viney RC; Pickard AS; Cella D; Shaw JW;
Pharmacoecon Open; 2024 Jan; 8(1):49-63. PubMed ID: 38060096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
